Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease

Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease

Despite therapeutic progress in recent years with the introduction of targeted therapies (daratumumab, elotuzumab), multiple myeloma remains an incurable cancer. The question is therefore to investigate the potential of targeted alpha therapy, combining an anti-CD138 antibody with astatine-211, to d...

Full description

Bibliographic Details
Main Authors: Sébastien Gouard, Catherine Maurel, Séverine Marionneau-Lambot, Delphine Dansette, Clément Bailly, François Guérard, Nicolas Chouin, Ferid Haddad, Cyril Alliot, Joëlle Gaschet, Romain Eychenne, Françoise Kraeber-Bodéré, Michel Chérel
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
Targeted alpha therapy
astatine-211
multiple myeloma
CD138
minimal residual disease
Online Access:https://www.mdpi.com/2072-6694/12/9/2721

Internet

https://www.mdpi.com/2072-6694/12/9/2721

Similar Items